NEW YORK, Sept 11 – AlphaGene of Woburn, Mass., said Tuesday it has signed an agreement with Wayne State University to study malignant brain tumor cell types using gene expression technology.
Under the terms of the deal, AlphaGene will contribute its expertise in functional genomics, while Wayne State University will provide its research capabilities. Financial terms of the deal were not disclosed.
AlphaGene and Wayne State will also look to correlate gene expression patterns with treatment regimens and aim to develop new diagnostic and prognostic methods.
"We believe that by combining our technologies and expertise, we will gain a better insight into the genetic causes of the disease, and in so doing, we will identify new validated drug targets and markers for these difficult to treat brain tumors,” Donald McCarren, president and CEO of AlphaGene, said in a statement.
Wayne State University is currently developing a bank of brain tumors and normal blood specimens from consenting patients.
AlphaGene is a biotechnology company conducting research relating to neuro-degenerative diseases and cancer.